Biosimulation Market

In 2025, the software segment accounted for the largest share of the biosimulation market, as software platforms serve as the foundation for modeling, simulation, and predictive analytics across the drug development lifecycle. These solutions enable researchers to evaluate drug candidates, simulate biological processes, assess safety and efficacy profiles, and support regulatory decision-making without relying solely on laboratory or clinical studies. The growing adoption of model-informed drug development (MIDD), increasing use of AI-powered simulation tools, and rising demand for computational approaches to address complex therapeutic challenges have further strengthened software adoption. Additionally, continuous advancements in modeling accuracy, cloud connectivity, high-performance computing, and integrated analytics capabilities are driving organizations to invest in sophisticated biosimulation software to accelerate innovation, improve development outcomes, and optimize research expenditures.

The drug discovery segment accounted for the lagest share of the biosimulation market in 2025, driven by the increasing utilization of computational technology in the process of target identification, lead optimization, and candidate selection. This enables companies to reduce both time and cost involved in experiment-based operations. Biosimulation applications have been commonly used in drug discovery as part of the process, including molecular interaction prediction, evaluation of physiochemical properties of drug candidates, biological activity assessment, and prioritization of the same. Increasing importance being assigned to artificial intelligence and machine learning within the field of drug discovery makes biosimulation imperative, as scientists are able to quickly make decisions in the course of their research. In addition to this, greater emphasis on more complicated drug types, like biologics, peptides, protein degraders, and cell and gene therapies, necessitates biosimulation.

By modality, the antibody segment accounted for the largest share of the biosimulation market in 2025 due to the rising scope and use of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and other types of antibody molecules for the treatment of different disease conditions. As the complexity of designing antibodies increases, the need for simulation techniques for modeling interactions between antibodies and antigens, affinity testing, assessing developability, predicting immunogenicity, and selecting candidates is also increasing. The increasing importance of computer-aided approaches for enhancing antibody properties, minimizing the need for experimental screenings, and reducing time in product development is leading many pharmaceutical and biotechnology organizations toward using simulation techniques in their development process. The success of existing antibody therapeutics, along with the emergence of novel biologic agents, is further propelling the segment.

In 2025, PK/PD modeling emerged as the dominant application area within the biosimulation market because of its significance in assessing the relationship among the exposure, efficacy, and safety of drugs through the life cycle of their development process. The popularity of PK/PD modeling is largely due to the fact that the modeling helps in achieving an optimal dose and also serves several other purposes, including the identification of exposure-response relationships, informing treatment decisions, and performing risk assessment. Many pharmaceutical and biotechnology companies rely on PK/PD models to streamline their development processes, determine optimal doses, and minimize risks associated with costly clinical trials. With growing acceptance of model-informed evidence and increasing reliance on simulations in drug development processes, the significance of PK/PD modeling has only grown, making it the most dominant segment within the biosimulation market.

The oncology segment led the biosimulation market in 2025, representing the largest share of all biomedical fields. This market position is based on a high number of oncology research programs being conducted in comparison to other therapeutic areas, coupled with an increased number of targeted and immunotherapy trials and the complexity of biological systems associated with cancer. Moreover, biosimulation has become an essential tool for oncologists, offering tumor growth modeling, biomarker identification, patient stratification, dose optimization, and predicting treatment response. The increase in oncology clinical studies, as well as the need to evaluate combination therapies and personalized medicine, has helped further accelerate the growth of advanced modeling and simulation technologies. Impacts of ongoing investments in cancer research from pharmaceutical companies, biotechnology companies, and academic institutions continue to drive the use of biosimulation tools throughout the oncology drug development process.

By deployment model, on-premises solutions accounted for the largest share of the biosimulation market in 2025. The segment maintained its leading position due to the preference of pharmaceutical and biotechnology organizations to maintain direct control over sensitive research data, proprietary models, and computational infrastructure. Many organizations continue to operate established in-house simulation environments that support critical activities such as drug candidate evaluation, pharmacokinetic analysis, and predictive modeling. On-premises deployments also offer greater flexibility for customization, seamless integration with internal R&D systems, and compliance with stringent data governance requirements. In addition, the significant investments made by large enterprises in high-performance computing infrastructure and validated software environments have contributed to the continued prominence of on-premises deployment models within the biosimulation market.

Due to the extensive use of modeling and simulation technologies across the drug discovery and development continuum, pharmaceutical and biotechnology companies emerged as the largest contributors to the biosimulation market in 2025. These end-user organizations increasingly utilize biosimulation in candidate prioritization, study design optimization, assessment of therapeutic effectiveness, and enhancing the overall efficiency of development programs. As they continue to explore innovative treatment options, such as biologics, gene therapy, and precision medicine, there is more use of advanced simulation tools to help address complex scientific problems. Additionally, the increasing size of drug pipelines and the need to improve R&D productivity have led to greater adoption of biosimulation platforms by pharmaceutical and biotechnology companies, which assist with making better-informed decisions throughout the development process while reducing program risk.